Page 146 - 2022_02-Haematologica-web

L. Traeger et al.
16.Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105 (2):260-272.
17. Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131(8):899-910.
18. Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. 2004;1695(1-3):55-72.
19. Morreale FE, Walden H. Types of ubiquitin ligases. Cell. 2016;165(1):248-248.
20.hen M, Schmitt S, Buac D, Dou QP. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets. 2013;17(9):1091-1108.
21. Stewart MD, Ritterhoff T, Klevit RE, Brzovic PS. E2 enzymes: more than just middle men. Cell Res. 2016;26(4):423-440.
22. Ardley HC, Robinson PA. E3 ubiquitin ligas- es. Essays Biochem. 2005;41:15-30.
23. Weber J, Polo S, Maspero E. HECT E3 ligas- es: a tale with multiple facets. Front Physiol. 2019;10:370.
24.Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, Nemeth E. High-throughput screen- ing of small molecules identifies hepcidin antagonists. Mol Pharmacol. 2013;83(3):681- 690.
25. Meynard D, Kautz L, Darnaud V, Canonne- Hergaux F, Coppin H, Roth M-P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
26. Xiao X, Alfaro-Magallanes VM, Babitt JL. Bone morphogenic proteins in iron home- ostasis. Bone. 2020;138:115495.
27. Shearwin-Whyatt LM, Brown DL, Wylie FG, Stow JL, Kumar S. N4WBP5A (Ndfip2), a Nedd4-interacting protein, localizes to multi- vesicular bodies and the Golgi, and has a
potential role in protein trafficking. J Cell Sci.
2004;117(Pt 16):3679-3689.
28. Harvey KF, Shearwin-Whyatt LM, Fotia A,
Parton RG, Kumar S. N4WBP5, a potential target for ubiquitination by the Nedd4 fami- ly of proteins, is a novel Golgi-associated protein. J Biol Chem. 2002;277(11):9307- 9317.
29. Ingham RJ, Gish G, Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular archi- tecture. Oncogene. 2004;23(11):1972-1984.
30. Kelsall IR, Duda DM, Olszewski JL, et al. TRIAD1 and HHARI bind to and are activat- ed by distinct neddylated Cullin-RING ligase complexes. EMBO J. 2013;32(21):2848-2860.
31. Nam H-J, Lane MD, Padron E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol. 2007;81(22):12260- 12271.
32.Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16(3):270-276.
33. Barghout SH, Schimmer AD. E1 Enzymes as Therapeutic Targets in Cancer. Pharmacol Rev. 2021;73(1):1-56.
34.Groettrup M, Pelzer C, Schmidtke G, Hofmann K. Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem Sci. 2008;33(5):230-237.
35. Jin J, Li X, Gygi SP, Harper JW. Dual E1 acti- vation systems for ubiquitin differentially regulate E2 enzyme charging. Nature. 2007;447(7148):1135-1138.
36. Canaan A, Yu X, Booth CJ, et al. FAT10/diu- biquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol Cell Biol. 2006;26(13):5180-5189.
37. Canaan A, DeFuria J, Perelman E, et al. Extended lifespan and reduced adiposity in mice lacking the FAT10 gene. Proc Natl Acad
Sci U S A. 2014;111(14):5313-5318.
38. Wang F, Zhao B. UBA6 and its bispecific pathways for ubiquitin and FAT10. Int J Mol
Sci. 2019;20(9):2250.
39. Elmehdawi F, Wheway G, Szymanska K, et
al. Human homolog of drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies. Exp Cell Res. 2013;319(3):161-172.
40. Scott DC, Rhee DY, Duda DM, et al. Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation. Cell. 2016;166(5):1198-1214.
41. Foot NJ, Leong YA, Dorstyn LE, et al. Ndfip1- deficient mice have impaired DMT1 regula- tion and iron homeostasis. Blood. 2011;117(2):638-646.
42. Foot NJ, Gembus KM, Mackenzie K, Kumar S. Ndfip2 is a potential regulator of the iron transporter DMT1 in the liver. Sci Rep. 2016;6:24045.
43. Foot NJ, Dalton HE, Shearwin-Whyatt LM, et al. Regulation of the divalent metal ion transporter DMT1 and iron homeostasis by a ubiquitin-dependent mechanism involving Ndfips and WWP2. Blood. 2008;112(10): 4268-4275.
44. Yanatori I, Kishi F. DMT1 and iron transport. Free Radic Biol Med. 2019;133:55-63.
45. Oliver PM, Cao X, Worthen GS, et al. Ndfip1 protein promotes the function of itch ubiqui- tin ligase to prevent T cell activation and T helper 2 cell-mediated inflammation. Immunity. 2006;25(6):929-940.
46. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-2463.
47. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.
488
haematologica | 2022; 107(2)